Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3803812 | 0.87 | MAPK1 (0.40) | MAPK1L3MBTL1HPGDKDM4EALDH1A1 | |
| SCHEMBL29530414 | 0.82 | MAPK1 (0.59) | MAPK1L3MBTL1HPGDSMN1; SMN2KDM4E | |
| SCHEMBL1313329 | 0.82 | MAPK1 (0.59) | MAPK1L3MBTL1HPGDSMN1; SMN2KDM4E | |
| SCHEMBL27525988 | 0.81 | HPGD (0.56) | MAPK1L3MBTL1HPGDSMN1; SMN2KDM4E | |
| SCHEMBL30525604 | 0.79 | SMN1; SMN2 (0.42) | MAPK1L3MBTL1HPGDSMN1; SMN2KDM4E | |
| SCHEMBL25330718 | 0.79 | MAPK1 (0.37) | MAPK1L3MBTL1HPGDKDM4EALDH1A1 | |
| SCHEMBL5233239 | 0.78 | MAPK1 (0.41) | MAPK1L3MBTL1HPGDKDM4EALDH1A1 | |
| SCHEMBL31328995 | 0.78 | NPC1 (0.49) | NPC1RAB9ASQOR | |
| SCHEMBL9929711 | 0.77 | MEN1 (0.42) | MAPK1L3MBTL1HPGDSMN1; SMN2KDM4E | |
| SCHEMBL22978638 | 0.77 | SMN1; SMN2 (0.44) | MAPK1L3MBTL1HPGDSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023185811-A1 | NOVEL HETEROCYCLIC COMPOUND | 首药控股(北京)股份有限公司 | 2023-10-05 | — | — | WO | disclosed |
| EP-2133340-B1 | Novel benzazepine derivatives | GLAXO GROUP LTD (GB) | 2013-01-16 | — | — | EP | disclosed |
| EP-2187893-A2 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | Anacor Pharmaceuticals, Inc. (US) | 2010-05-26 | — | — | EP | disclosed |
| WO-2010028005-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2010-03-11 | — | — | WO | disclosed |
| EP-2133340-A1 | Novel benzazepine derivatives | Glaxo Group Limited (GB) | 2009-12-16 | — | — | EP | disclosed |
| WO-2009111676-A2 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | ANACOR PHARMACEUTICALS, INC (US) | 2009-09-11 | — | — | WO | disclosed |
| US-20070219234-A1 | Thienopyridine Derivatives | SANKYO COMPANY, LIMITED (JP) | 2007-09-20 | — | — | US | disclosed |
| EP-1764367-A1 | THIENOPYRIDINE DERIVATIVES | Sankyo Company, Limited (JP) | 2007-03-21 | — | — | EP | disclosed |
| US-20060189639-A1 | Antagonists of the mGlu receptor and uses thereof | ABBOTT LABORATORIES | 2006-08-24 | — | — | US | disclosed |
| WO-2006081072-A1 | ANTAGONISTS OF THE MGLU RECEPTOR AND USES THEREOF | ABBOTT LABORATORIES (US) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189639-A1 | Antagonists of the mGlu receptor and uses thereof | GRM3, GRM4, GRIA4 | MAPK1 3105/4885L3MBTL1 1141/4885HPGD 1000/4885 |
| US-20070219234-A1 | Thienopyridine Derivatives | RASGRP1, NRAS, HRH3 | MAPK1 520/4885L3MBTL1 4177/4885HPGD 2215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.